Novavax to Host Conference Call to Discuss First Quarter 2022 Financial Results and Operational Highlights on May 9, 2022
05/02/2022 - 04:02 PM
GAITHERSBURG, Md. May 2, 2022 Monday, May 9, 2022 , following the close of U.S. financial markets. Details of the event and replay are as follows:
Conference call details:
Date:
May 9, 2022
Time:
4:30 p.m. U.S. Eastern Daylight Time (EDT)
Dial-in number:
833) 974-2381 (Domestic) or (412) 317-5774 (International)
Webcast:
ir.novavax.com/events
Participants will be prompted to request to join the Novavax, Inc. call. To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
Replay details:
Date:
Available starting at 7:30 p.m. EDT, May 9, 2022 until 11:59 p.m. U.S. EDT, May 16, 2022
Dial-in number:
877) 344-7529 (Domestic) or (412) 317-0088 (International)
Passcode:
9339969
Webcast:
ir.novavax.com/events , until August 9, 2022
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu*, its quadrivalent influenza investigational vaccine candidate. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter , LinkedIn , Instagram and Facebook .
*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.
Contacts: Investors Novavax, Inc.ir@novavax.com
Media Alison Chartan | 240-720-7804Laura Keenan Lindsey | 202-709-7521media@novavax.com
https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-first-quarter-2022-financial-results-and-operational-highlights-on-may-9-2022-301537188.html
SOURCE Novavax, Inc.
NVAX Rankings
#5166 Ranked by Stock Gains
NVAX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Gaithersburg
About NVAX
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
